About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

21.27 -0.10 (-0.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,988,583
Open 21.37
Bid (Size) 21.08 (10)
Ask (Size) 21.59 (5)
Prev. Close 21.37
Today's Range 21.12 - 21.59
52wk Range 18.64 - 24.34
Shares Outstanding 315,048,788
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
These stocks are both experts in their respective fields. 
Via The Motley Fool
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'
Despite MacroGenics' clinical activity, unexpected adverse events raise concerns. Analysts adjust ratings and price targets. 
Via Benzinga

Performance

YTD
-11.12%
-11.12%
1 Month
-6.30%
-6.30%
3 Month
+4.32%
+4.32%
6 Month
+1.58%
+1.58%
1 Year
+9.08%
+9.08%

More News

Read More
Just Say No to Drugs: 3 Pharma Stocks to Avoid
Via InvestorPlace
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
From Exelixis, Inc.
Via Business Wire
The Analyst Verdict: Exelixis In The Eyes Of 5 Experts
Via Benzinga
Technical Signals Point to a Possible Breakout for EXELIXIS INC.
Via Chartmill
What Analysts Are Saying About Exelixis Stock
Via Benzinga
2 Stocks Under $30 to Buy and Hold
Via The Motley Fool
Exelixis (EXEL) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
EXEL Stock Earnings: Exelixis Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
The Top 3 Biotech Stocks to Buy in April 2024
Via InvestorPlace
NASDAQ:EXEL is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
From Exelixis, Inc.
Via Business Wire
NASDAQ:EXEL is an undervalued gem with solid fundamentals.
Via Chartmill
3 Biotech Stocks to Buy on the Dip: March 2024
Via InvestorPlace
4 Magnificent Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Via The Motley Fool
Topics Stocks
Exposures US Equities
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
Via Talk Markets
2 Biotech Stocks to Buy Hand Over Fist in March
Via The Motley Fool
3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success
Via InvestorPlace
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
Via Chartmill
4 Thrilling Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Via The Motley Fool
Topics Stocks
Exposures US Equities
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
From Exelixis, Inc.
Via Business Wire
Around $4M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
Via FinancialNewsMedia
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.